Ascension Alexian Brothers hospital in Elk Grove is conducting new trials for Alzheimer’s treatments, focusing on drugs targeting amyloid plaques and tau proteins. Patients aged 55-80 with early dementia signs can participate in the studies. Notable advancements include subcutaneous administration of remternetug and a broader strategy for more combined therapies in the future. There’s emphasis on early diagnosis for effective treatment.
Ascension Alexian Brothers hospital in Elk Grove Village is renewing its efforts in Alzheimer’s treatment research, more than ten years after conducting trials for the now-approved drugs used to slow the disease’s progression. Dr. Concetta Forchetti, leading the studies at the hospital’s neurosciences institute, emphasises the significance of these new trials, which aim to explore potential treatments beyond the existing medications.
Currently, patients experiencing mild cognitive impairments can participate in trials for two FDA-approved drugs: donanemab (Kisunla) and lecanemab (Leqembi). Both medications target amyloid plaques in the brain. The hospital previously trialed bapineuzumab in 2010, which did not reach approval but informed subsequent drug development.
A new drug called remternetug is also under investigation, distinctively targeting amyloid proteins through subcutaneous injection instead of intravenous methods. This innovative approach allows patients to administer their treatment at home, enhancing convenience compared to monthly IV infusions. Participants in this study must be aged between 55 and 80 and exhibit early onset dementia signs.
Another ongoing study focuses on tau proteins, known for their role in Alzheimer’s. Currently in phase 2B of a three-phase trial, this study involves approximately 400 participants aged 60 to 80. The focus here is on evaluating the drug’s safety and efficacy, paving the way for broader treatments if successful.
Dr. Forchetti envisions a future where combined therapies, possibly involving tau and amyloid blockers, can effectively combat Alzheimer’s disease. The emphasis remains on early diagnosis as treatments are proven more effective when initiated promptly. Despite this, many patients arrive at the clinic with advanced stages of the disease, underscoring the need for increased awareness and early intervention.
Additionally, the hospital supports studies for patients in severe cognitive stages, aiming to enhance the functionality of remaining healthy brain cells. Dr. Forchetti balances her role in research while treating patients frequently, with each new patient undergoing thorough evaluations, including cognitive testing, MRIs, and consultations with family.
Dr. Brian Leahy conducts further cognitive assessments to aid in diagnosis, followed by supportive therapy conducted by Dr. Konstantinos Kostas for both patients and their families. The hospital’s foundation has recently funded a social worker to assist families in accessing necessary resources such as care options, underscoring the integrated approach to treating Alzheimer’s.
This multidisciplinary collaboration at Elk Grove hospital ensures a comprehensive support system is in place for both patients and families, highlighting the collective efforts in advancing Alzheimer’s research and care.